1. Introduction {#sec1}
===============

Cornea is mostly composed of collagen and water and is enveloped by epithelium and endothelium \[[@B1]\]. These layers cooperate to ensure tissue homeostasis by providing adequate corneal transparency and reliability \[[@B1]\]. After injury, corneal epithelial cells regenerate and restore the physiologic tissue architecture. In addition, a concomitant nerve regrowth and a controlled neovascularization of the damaged surface may occur \[[@B2], [@B3]\]. Cellular loss needs replacement by cell growth and migration \[[@B3]\]. The mechanism driving the epithelialization involves a multiplicity of cells stimulated by serum growth factors (GFs) ([Table 1](#tab1){ref-type="table"}) \[[@B4]--[@B6]\], mostly contained in platelet-*α* granules and issued by the same GFs into the blood during stress and tissue repair \[[@B4]--[@B10]\]. The great quantity and accessibility of GFs and other signaling proteins in platelets with a consequent inhibition of cell apoptosis and improvement of cell proliferation, differentiation, and migration suggested the extensive use of platelet derivatives for clinical and surgical aims in regenerative medicine ([Table 1](#tab1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}) \[[@B7], [@B11]\]. Indeed, GFs, binding to tyrosine kinase or G protein-coupled receptor families, drive both the inflammatory process and the stroma remodeling through autocrine, juxtacrine, or, most commonly, paracrine means. Thus, the transcription of critical proteins for cell cycle returning to prewounding levels after the tissue healing occurs ([Table 1](#tab1){ref-type="table"}) \[[@B12], [@B13]\].

Particularly, serum GFs such as epidermal growth factor (EGF), hepatocyte growth factor (HGF), and keratinocyte growth factor (KGF) stimulate corneal wound closure accelerating the healing time. Moreover, transforming growth factor-*β*1/*β*2 (TGF *β*1/*β*2) induces myofibroblast from fibroblast differentiation coupled to corneal opacification (corneal haze) ([Table 1](#tab1){ref-type="table"}) \[[@B14]--[@B16]\]. Moreover, cytokines derived from the trigeminal nerve like substance P, neuropeptide y, catecholamines, and acetylcholine are positively involved in corneal healing \[[@B17]\]. Besides, an aged decreased response to mitogens mediated by alterations in the expression and activity of cyclin-dependent kinase inhibitors (p27KIP1, p16INK4A, and p21CIP1) appears to be involved in a lacking or a damaging of cellular repair processes \[[@B3]\].

Toward this context, the lachrymal film plays a critical role such as resource of GFs \[[@B18]--[@B24]\] since the lack of tear epitheliotropic support promotes corneal opacity onset with consequent visual impairment \[[@B25]\]. On the other hand, tear upregulation drives corneal epithelial hyperplasia, excessive deposition of extracellular matrix, and hypervascularization with cornea conjunctivalization \[[@B8]\]. Here, we report the different concentrations of each GF in the human serum with respect to tears. The levels of transforming growth factor *α* (TGF-*α*), hepatocyte growth factor (HGF), TGF*β*1/2, and nerve growth factor (NGF) resulted to be even more elevated in serum than in tears.

Failure of the corneal repair mechanisms leads to a chronic pathologic condition as persistent epithelial defects (PED) or dry eye syndrome (DES) \[[@B15]\]. PED result from several factors such as aging, chemical burns, systemic disorders, and drugs \[[@B26]\] ([Figure 1](#fig1){ref-type="fig"}). Nevertheless, DES, associated to tear deficit or tear inefficiency, is able to promote the corneal epithelial instability and inflammation \[[@B27], [@B28]\] supporting PED syndrome. DES is caused by lacrimal gland imbalance often connected to systemic inflammatory diseases \[[@B29]--[@B32]\], such as Sjogren\'s syndrome \[[@B33]\], rheumatoid arthritis \[[@B31]\], diabetes \[[@B34]\], systemic lupus erythematosus, acne rosacea, and Graves\' disease \[[@B35]\]. In addition, hormonal modifications, drugs (e.g., systemic antihistamines, diuretics, and topical beta blockers for glaucoma therapies), and surgeries (e.g., photorefractive keratectomy and laser*in situ* keratomileusis) \[[@B36]\] as well as the repeated use of contact lenses could be involved in DES development \[[@B27]\]. On the basis of mechanistic criteria, International Dry Eye WorkShop has characterized two main subtypes of the disorder (aqueous deficiency and evaporative dry eye) both interested by tear film instability and symptoms of discomfort \[[@B28], [@B37]\]. Ocular dryness or irritation might increase light sensitivity, foreign body sensation, red eyes, poor vision, and daily life limitations which are the most referred symptoms which have great impact on patient quality of life \[[@B37], [@B38]\]. The best clinical marker for DES diagnosis and for the severity assessment is represented by the improved tear osmolarity \[[@B39]\]. In addition, tear production is currently evaluated by Schirmer\'s testing, fluorescein clearance, and fluorescein tear break-up time (TBUT). The ocular surface damage is estimated through dye staining (fluorescein and lissamine green) while the severity of subjective symptoms is assessed by subjective scored questionnaires (like OXFORD score and Ocular Surface Disease Index) \[[@B37], [@B38]\].

Up to now, there is no gold standard therapy for DES or PED \[[@B40]--[@B42]\]. Current therapeutic strategies require the accurate identification of etiologic mechanisms that cause the corneal injury by providing epitheliotropic factors and enhancing tear replacement \[[@B26], [@B43], [@B44]\]. When standard therapeutic options fail, the main treatment purpose is the increased patient comfort and corneal moisture through the instillation of artificial tears, corticosteroids, antibiotics, and use of bandage contact lenses \[[@B30], [@B45]--[@B47]\]. However, natural tears have a particular composition of water, salts, hydrocarbons, proteins, and lipids that cannot be restored by pharmacological alternatives \[[@B25]\]. Furthermore, artificial tear substitutes contain chemical preservatives associated with toxic and allergic reactions, especially for those patients with sensitive eyes \[[@B6]\]. Moreover, the repeated instillation of topical corticosteroids could be associated with long-term side effects including cataracts and increased intraocular pressure \[[@B49]\]. For these motivations, alternative therapies like silicone punctal plug insertion, botulinum neurotoxin type A, nutritional supplements (essential fatty acids, including omega-3, linoleic acid, and gamma-linoleic acid), and topical 0.05% solution of cyclosporine A have been proposed \[[@B50]--[@B56]\]. However, changes in life style as an increased water intake and reduction of alcohol consumption, indoor humidifiers, and air filters or cleaners have been recommended \[[@B57]\].

A debated aspect of the treatment of corneal diseases is focused on the use of novel regenerative instruments for corneal regeneration \[[@B58]--[@B61]\]. The evidence regarding the key role of several GFs for the integrity of the ocular surface ([Table 1](#tab1){ref-type="table"}) fits the use of single recombinant GFs in several human corneal degenerative disorders \[[@B58]--[@B62]\]. Nerve growth factor (NGF) alteration in corneal diseases has been largely evaluated; NGF pathway alteration has been tested in an animal model by demonstrating NGF to be involved in corneal healing and in sensory denervation \[[@B63]\]. Moreover, in studies evaluating human being, low tears level of NGF has been proved to be reduced in eyes affected by dry eye \[[@B64]\] and has been proved to be effective in several corneal diseases such as neurotrophic keratitis, immune corneal ulcer, and HSV keratitis and after cataract surgery \[[@B65]\]. Clinical trials are ongoing to evaluate therapy with NGF eye drops in corneal diseases and first results seem to be very promising \[[@B66]\].

In addition, a conditioned medium derived from human uterine cervical stem cells has been tested for corneal epithelial healing \[[@B67]\], and a therapeutically ocular surface medium, routinely used to culture epithelial cells, was suggested as novel eye drops for DES and PED \[[@B68]\].

Among these emerging therapies, the use of biologic eye drops derived from both human peripheral \[[@B44], [@B51], [@B69]--[@B76]\] and umbilical cord blood serum \[[@B77]--[@B79]\] plays a crucial role in several corneal diseases. Previous*in vitro* experiments showed that corneal epithelial cell morphology and cell functions are better maintained by human serum eye drops (SE) than pharmaceutical tear substitutes \[[@B80]\].

The first applications of human SE to support corneal regeneration were performed in 1975 in corneal alkali injury cases \[[@B81]\]; later, in 1984, Fox et al. \[[@B82]\] reported the use of SE in a DES. Later, SE have gained a therapeutic dignity in ophthalmology as a new concept to manage wounded cornea \[[@B83], [@B84]\]. To date, despite the fact that SE therapy could avoid drug side effects, its use is restricted and is not universally recognized as therapeutic option although several aspects of the whole regenerative medicine are still debated \[[@B11]\].

Here, we critically analyzed the current applications of SE in corneal diseases like DES and PED by focusing on crucial topics for its production and the current legislative restrictions in support of its use. To analyze the SE therapeutic achievement, we reported the most recent published randomized clinical trials (RTCs) and ongoing studies where this kind of treatment has been applied and compared to standard and other emergent treatments in severe ocular conditions.

2. Legislative, Ethical, and Technical Implications on the Use of Serum Eye Drops {#sec2}
=================================================================================

The use of SE obtained from patient peripheral whole blood (autologous) or from healthy donor (nonautologous or allogenic) represents a biological therapeutic strategy influencing and promoting the corneal restitution \[[@B11], [@B69], [@B84]\]. The rationale for its use arises from its strong similarity to tears, in regard to pH (7.4) and osmolarity (298 mml for tears and 296 mml for serum) \[[@B85]\] as well as its biochemical constitution. In addition, SE offer the same platelet derived antibacterial and anti-inflammatory effect*in vivo* \[[@B86]\].

Despite the fact that multiple studies supported the safety and efficacy of SE over standard treatments, SE have not yet been considered for approval by Food and Drug Administration, in the United States \[[@B8]\].

For this reason, SE are not a recognized treatment and are not covered by most of medical insurances \[[@B83]\]. In addition, despite the improved reliability of current serologic tests for HBs-Ag, anti-HCV, anti-HIV-1/2, and syphilis detection, the use of allogenic SE is associated with the immunologic and infectious implications of donor exposure \[[@B87]\]. However, even though autologous SE should be considered the best choice, patients with absolute contraindications to provide blood as a result of specific diseases or conditions (e.g., bacteremia) or who are unable to tolerate frequent venipunctures are eligible for the treatment with healthy donor SE. The allogenic SE, subjected to severe laboratory checks, can be used as an effective alternative treatment showing comparable clinical results to the autologous one \[[@B74], [@B87]\].

The established criteria for donor enrollment and for blood collection include hemoglobin level higher than 11 g/dL (hematocrit \> 33%) and exclude subjects presenting risk of bacteremia and cardiovascular diseases deferring pregnant women and children. Despite the absence of absolute prohibitions, the use of SE in children is restricted to avoid repeated required venipunctures and limiting instillation of potentially infectious donor sera in such patients \[[@B87], [@B88]\]. In these cases, if traditional therapy with artificial tears, antibiotics, or steroids is not effective, the topical cyclosporine or the conjunctival flap can be applied to improve the corneal conditions \[[@B88]\].

According to the current protocols, blood samples should be collected with previous informant consent and transferred into a sterile kit or blood bag without anticoagulant and treated under sterile conditions (laminar flow hood) ([Table 2](#tab2){ref-type="table"}). A sufficient time has to be dedicated to the patient to illustrate properly the treatment and the need for repeated blood sampling. As shown in [Table 2](#tab2){ref-type="table"}, the routine production of SE is frequently affected by the lack of recognized procedures \[[@B11], [@B86]\]. However, the proper management, handling, and storage of final product are essential for the successful treatment avoiding side effects.

To date, many laboratory protocols have been published for SE production with variable dilutions of serum (from 20% to 100%) and with differences in clotting phase, centrifugation time, and speed \[[@B89], [@B90]\] ([Table 2](#tab2){ref-type="table"}). According to previous studies, clotting time is critical to obtain ideal concentrations of EGF, TGF-*β*-1, and fibronectin in the collected serum \[[@B86]\]. In addition, a proper serum dilution is recommended to reduce the antiproliferative effect of TGF-*β* which results five times higher in human serum than in tears \[[@B86]\]. Usually, 0.9% sodium saline or balanced salt solutions are utilized as diluents and preservatives solutions are not usually added to decrease the risk of induced toxicity. For the lack of preservatives, microbial cultures as well as the antibiotic therapy are recommended \[[@B86]\]. Finally, to preserve the biologic activity, the SE should be frozen in blood banks at −70°C until its use or at −20°C for a month and protected from light to prevent the degradation of vitamin A ([Table 2](#tab2){ref-type="table"}).

Depending on clinical conditions, the frequency of instillations of SE may go from every 15 minutes to two times per day; also the duration of the reported treatment widely ranged from 3 days to a maximum of 36 months. In most cases, the improvement appears after a brief period of therapy (from 1 to 4 weeks) \[[@B91]\]. Studies reported one case of corneal immunoglobulin deposition, scleral vasculitis, epithelial erosion, conjunctivitis, decreased corneal sensitivity, inflammatory response, infections, and an isolated case of mycosis \[[@B91]\]. Recently, to avoid immunity complications, Anitua et al. have characterized a plasma rich in GF without IgE and complement suggesting its use in autoimmune diseases \[[@B83]\]. Until now, the few published data on clinical complications associated with SE have demonstrated the safety of this therapy. However, limitations in published studies as discussed below are observed.

3. Clinical Applications and Study Results {#sec3}
==========================================

As shown in [Table 2](#tab2){ref-type="table"}, several studies investigated the role of SE treatment mostly in corneas affected by DES and PED.

Despite the fact that most of the authors found objective and subjective wellbeing after the treatment with SE, the comparison of clinical results is complex because data have been obtained from nonhomogeneous populations affected by several unrelated corneal diseases. In addition, the technical preparation of SE shows different dilutions obtained with different solutions, clotting phases, centrifugation forces, and time intervals, as well as different storage temperatures and times that can modify the final clinical outcomes and healing times as shown in [Table 2](#tab2){ref-type="table"}.

Recent results have confirmed the efficacy of SE with respect to conventional therapy \[[@B92]\] in patients with severe DES or PED \[[@B80], [@B93]\] both by improving tear film stability and providing subjective comfort. Moreover, two recent prospective interventional studies \[[@B94], [@B95]\], on large cohorts of patients with PED treated with SE after ocular surgery, showed a significant or moderate improvement of delayed heal. In particular, Chen et al. \[[@B94]\] showed that 165 patients treated with 20% SE after penetrating keratoplasty drastically reduced postoperative PED when compared to patients that received artificial tears. In addition, Lekhanont et al. \[[@B95]\] evaluated SE for PED in 181 patients showing a high proportion (93.92%) of complete corneal epithelialization in only 4 days with low rate of adverse reactions.

Case reports have been described about the use of SE in other corneal diseases like ocular graft versus host disease \[[@B96], [@B97]\], bullous keratopathy \[[@B98]\], fulminant bilateral*Haemophilus influenzae* keratitis \[[@B99]\], neurotrophic corneal ulcer \[[@B100]\], anterior tissue necrosis after porous orbital implant \[[@B41]\], and Mooren\'s ulcer \[[@B101]\]. In all these cases, SE allowed a complete corneal healing with an effective improvement of the clinical conditions.

Despite many promising results, some recent studies have questioned the validity of this treatment. A prospective cross-sectional study on 34 patients did not find that SE could be effective in secondary Sjogren\'s syndrome due to elevated serum proinflammatory cytokine levels \[[@B102]\]. Moreover, a single prospective study on 17 patients with DES demonstrated the short-term benefit of SE, which persisted up only to three months after the end of therapy \[[@B103]\]. In 2013, Pan et al. \[[@B36]\] performed a meta-analysis identifying four randomized clinical trials, which compared SE with artificial tear treatment or saline solutions in patients with Sjogren\'s syndrome-related DES, non-Sjogren\'s syndrome DES, and postoperative DES. In conclusion, they advocated the need of recognized measures to define subjective symptoms and to assess the real effect of SE therapy for DES \[[@B36]\]. The use of SE was compared in randomized trials to unconventional biologic therapies, which have gained a growing interest, such as umbilical cord blood serum (CBS) \[[@B104], [@B105]\] and amniotic membrane transplant \[[@B106]\]. CBS is collected from umbilical vein after fetal delivery, manipulated, and collected similarly to peripheral serum \[[@B105]\]. CBS is considered a reliable source of undifferentiated mesenchymal stem cells \[[@B107], [@B108]\], which are self-renewal elements that are able to replace directly corneal keratocytes \[[@B105]\] and conjunctival, limbal \[[@B77]\], and retinal nerve cells \[[@B105]\]. In addition, CBS contains consistent levels of cytokines, GFs, fibronectin, prealbumin, and fatty oils that provide useful instruments for corneal differentiation \[[@B75], [@B109]\]. Moreover, CBS includes antibacterial agents as IgG, lysozyme, and complement but lower levels of vitamin A compared to peripheral serum \[[@B110]\]. Despite the reduced immunogenicity of CBS with respect to peripheral serum due to the lower levels of IgM anti-A, anti-B, and IgG2 \[[@B79], [@B108]\], the use of the first is naturally associated to donor exposure and increased infectious risk and subjected to obstetric factors which could modify GF levels \[[@B111]\].

Some authors tested CBS for PED \[[@B78], [@B104]\], DES \[[@B112]\], corneal diseases due to chemical burns \[[@B113]\], and surgeries associated \[[@B114], [@B115]\]. Due to prominent GFs, anti-inflammatory cytokines, and mesenchymal stem cell levels in CBS, some authors demonstrated the main effectiveness of CBS with respect to both conventional treatment and traditional SE in severe corneal diseases \[[@B78], [@B105], [@B110], [@B113]\]. For this reason, clinical ongoing trials are mostly focused on the comparative evaluation of the use of SE and CBS, especially in DES, PED, and ocular GVHD as summarized in [Table 3](#tab3){ref-type="table"}. In six ongoing studies reported on CBS eye drops, four are comparing CBS*versus* traditional SE and only one study analyzes amniotic membrane transplant*versus*SE in 180 patients with PED. Probably, promising results will arise from a large cohort randomized intervention single blind study which has enrolled 165 patients with diabetic retinopathy and penetrating keratoplasty comparing SE with standard treatments like corticosteroids and antibiotics. To date, there are no follow-up studies on SE or CBS eye drops treatment.

4. Future Directions {#sec4}
====================

Several fields of medicine are focusing on a regenerative approach to treat pathologic conditions affected by insensitivity and toxic reactions to standard therapies. In this context, tissue engineering and regenerative medicine are the present and the future aim of clinical therapy, especially where traditional treatments fail or promote severe adverse events.

A number of corneal conditions are often not fully managed by standard treatments and are characterized by intolerances and systemic effects. New treatments have to be considered. Subjective and objective results suggest that biologic therapies for corneal surface alterations like SE treatment could be an effective option. Indeed, the use of biologic eye drops provides the beneficial effects of vitamins, GFs, and cytokines by correcting delayed corneal healing pathways and by restoring balanced mechanisms \[[@B77], [@B79], [@B80]\].

However, the technical preparation of human serum for ocular instillation should require a well-equipped laboratory with specialized trained personnel as well as the respect of aseptic and quality procedures. In addition, methods for SE production (clotting time, centrifugation, and concentration) including the proper additive and GF doses should be optimized according to well-established guidelines and standardized quality controlled protocols \[[@B9], [@B36], [@B112]\]. Specifically, a proper serum dilution should be performed to reduce the TGF *β*1/*β*2 levels (present in more than 5 times in serum compared to tears), which would promote corneal scar formations and a delayed reepithelialization ([Table 1](#tab1){ref-type="table"}) \[[@B114]\]. Additionally, informed consent should be obtained from each patient in case of allogenic somministration to avoid ethical and juridical implications owing to blood transfusion practices and legislative restrictions should be carefully respected to minimize the immunological and infectious risks \[[@B11], [@B85]\].

5. Conclusions {#sec5}
==============

To date, clinical benefits of SE therapy have been demonstrated by some published studies. Most of the recent analyzed trials have tested the clinical results coming from SE treatment through the comparison with traditional therapeutic approaches such as artificial tears, antibiotics, or corticosteroids \[[@B80], [@B92], [@B93]\]. Several randomized studies suggest that SE treatment leads to an improved tear film stability and subjective comfort \[[@B29], [@B70], [@B84], [@B89], [@B92], [@B94], [@B95]\] by determining a faster epithelial healing time and a better corneal transparency without increase of vascularization or fibrosis. Moreover, several data have confirmed the safety and the almost absolute absence of toxic and side effects, especially in severe case of DES or in PED (except those related to an improper handling). A critical point of these published studies concerns the number of patients enrolled which are recurrently less than 100 \[[@B4], [@B13], [@B16], [@B35], [@B38], [@B39], [@B43], [@B85], [@B86], [@B96], [@B97]\] and the almost absence of long follow-up studies \[[@B70]\]. On the other hand, the evaluation of the ongoing studies on this therapy showed that the newer fields of clinical research are focusing on alternatives to SE like CBS. In this regard, many studies are testing CBS and its therapeutic properties and safety. However, further studies with large populations comparing biological therapies with the traditional ones in corneal diseases are needed to provide the best treatment tailored to the singular patient.

Forthcoming conclusions will guide future efforts useful to clinical advances. They will clarify the therapeutic limits and resources of these emergent biologic therapies for corneal surface alterations, especially for refractory patients.

6. Method of Literature Search {#sec6}
==============================

We performed a computerized literature search on studies and trials by using the following search terms in various combinations: serum eye drops, cord blood serum, dry eye, and persistent epithelial defects. This search was achieved without any time and language restrictions in the following databases: PubMed, <http://www.controlled-trials.com/>, <https://www.clinicaltrialsregister.eu/>, <https://eudract.ema.europa.eu/>, and <https://www.clinicaltrials.gov/>. The complete reference list of the most relevant studies was compared for the methodology of serum eye drops collection, preparation, and storage. Clinical trials reported in [Table 2](#tab2){ref-type="table"} were selected from studies published in the last 5 years (2010--2014).
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![Mechanisms involved in damaged cornea and serum growth factor regeneration pathways. Several corneal injures can promote pathological conditions such as PED or DES. Action of drugs, autoimmune diseases, aging, chemical insults, and postsurgical lesions can wound the cornea directly or indirectly through the imbalance of the lachrymal gland. Microscopically, these pathogenic conditions result in a loss of epithelial cells and microvilli, epithelial squamous metaplasia, and inflammation of the corneal surface. The corneal healing process can benefit from the promoting action of serum GFs. Once they are released, through tyrosine kinase receptors, they propagate their signal from the plasma membrane to the nucleus. Through explicit pathways and signaling cascades, GFs activate the expression of target genes involved in apoptosis, proliferation, cell differentiation, and migration. This synergistic action establishes regenerative effects with closure of epithelial lesions, revascularization, and neurorepair.](JOPH2015-396410.001){#fig1}

###### 

Main growth factors involved in corneal epithelial healing.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Growth factors   Utilized\                                                 Cellular target                                                              Cellular effects                                                                                                                                            Corneal effects                                                                                                  Tear level           Serum level              References
                   pathway                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ---------------- --------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- -------------------- ------------------------ ----------------------------
  EGF              EGFR/erbB1/HER1, erbB2/HER2/neu, erbB3/HER3, erbB4/HER4   Corneal epithelial cells (limbal region)                                     It increases epithelial migration and proliferation, inhibits corneal epithelial terminal differentiation, and upregulates activations of B4 integrins.     It stimulates epithelial wound closure accelerating the healing time.                                            2053 ± 312.4 pg/mL   199.74/±64.74 pg/mL      \[[@B16]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  TGF-*α*          EGFR/erbB1/HER1, erbB2/HER2/neu, erbB3/HER3, erbB4/HER4   Corneal epithelial cells                                                     It increases epithelial migration and proliferation and inhibits the expression of keratin K3.                                                              It leads edge extension in epithelial sheet migration during eyelid closure.                                     84 ± 19 pg/mL        120 to 207 pg/mL         \[[@B16], [@B20], [@B21]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  KGF              Ras-MAPK, PI3K/p70S6                                      Corneal epithelial cells                                                     It increases epithelial cell proliferation protecting them from hypoxia.                                                                                    It stimulates epithelial wound closure accelerating the healing time in the limbus zone.                         Not provided         10.63 ± 4.98 pg/mL       \[[@B57]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  HGF              c-Met, Ras-MAPK, PI3K/AKT, p70S6K, EGFR                   Corneal epithelial cells, fibroblasts                                        It increases epithelial cell migration and motility and proliferation and inhibits apoptosis.                                                               It stimulates epithelial wound closure.                                                                          200 pgmL^−1^         573.9 ± 142.8 pgmL^−1^   \[[@B18], [@B58]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  IGF-1            PI3K/AKT                                                  Corneal epithelial cells, fibroblasts                                        It increases epithelial cell proliferation, inhibits apoptosis, increases chemotaxis, and increases the expression of connexin 43 in corneal fibroblasts.   It stimulates epithelial wound closure improving gap-junctions.                                                  Not provided         173.5 ng/mL              \[[@B6]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  TGF\             TGF *β*-RI\                                               Corneal epithelial cells, fibroblasts (limbal and central region)            It inhibits epithelial cells proliferation, increases keratocyte proliferation, and promotes myofibroblast differentiation.                                 It promotes scar formations, delays reepithelialization, and inhibits angiogenesis.                              10 ng/mL             50 ng/mL                 \[[@B24]\]
  *β*1/*β*2        TGF *β*-RII                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  PDGF             PDGF-R                                                    Endothelial cell, fibroblasts, epithelial cells                              It increases endothelial cell proliferation, enhances fibroblast migration, and increases chemotaxis of epithelial cells.                                   It stimulates epithelial wound closure.                                                                          95--1330 ng/L        1.70 ng/mL               \[[@B22]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  FGF-2            FGF-R, heparan sulfate proteoglycans, RTKs                Corneal epithelial cells, fibroblasts (Bowman\'s and Descemet\'s membrane)   It increases epithelial, endothelial, and stromal cell proliferation.                                                                                       It stimulates epithelial wound closure and improves gap-junctions.                                               Not provided         8.3 ± 1.75 pg/mL         \[[@B13]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  NGF              TRKA-R                                                    Corneal epithelial cells, endothelial cells, fibroblasts                     It increases epithelial cell proliferation and differentiation.                                                                                             It stimulates epithelial wound closure, improves nerve regrowth, and induces inflammation and vascularization.   8.3 +/− 4.7 ng/ml    18.5 +/− 6.1 ng/mL       \[[@B19], [@B63], [@B64]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EGF: epidermal growth factor; TGF-*α*: transforming growth factor *α*; KGF: keratinocyte growth factor; HGF: hepatocyte growth factor; IGF-1: insulin growth factor 1; TGF*β*1/*β*2: transforming growth factor *β*1/*β*2; PDGF: platelet derived growth factor; FGF-2: fibroblastic growth factor 2; NGF: nerve growth factor.

###### 

Published studies on serum eye drops from 2010 to 2014.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of component                                       Study design                                                    Year   Patient number   Corneal disease                                   Clotting phase    Centrifugation/time     Dilution                                                   Storage              Results                                                                                                                                                               References
  ------------------------------------------------------- --------------------------------------------------------------- ------ ---------------- ------------------------------------------------- ----------------- ----------------------- ---------------------------------------------------------- -------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  100% AS                                                 Single-center\                                                  2013   181              Corneal epithelial defects after ocular surgery   2 h at RT         3000 g/15 min           None                                                       −20°C three months   It improves corneal healing.                                                                                                                                          \[[@B95]\]
                                                          prospective interventional study                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  50% AS                                                  Single-center prospective study                                 2014   28               Acute and chronic eye pathologies                 24--48 h at 4°C   4000 g/10 min           Sterile saline solution                                    −30°C six months\    It stabilizes and improves signs and symptoms in eyes previously treated with conventional therapy.                                                                   \[[@B92]\]
                                                                                                                                                                                                                                                                                                         −20°C\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                         three months                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS, CBS                                             Double-blind prospective randomized controlled clinical study   2011   33               Ocular chemical burns of grades III, IV, and V    Not provided      1800 g/10 min           Sterile balanced\                                          −20.0°C until use    Umbilical cord serum therapy is more effective than AS eye drops or artificial tears in ocular surface restoration after acute chemical injuries.                     \[[@B113]\]
                                                                                                                                                                                                                                              salt solution                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS versus AMT                                       Retrospective study                                             2014   42               Neurotrophic keratitis\                           2 h               3000 g/15 min           Sterile saline solution                                    Not provided         Amniotic membrane transplantation is more effective than AS in deep corneal ulcers with postherpes neurotrophic keratitis.                                            \[[@B106]\]
                                                                                                                                                  Corneal ulcers                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  100% AS                                                 Not provided                                                    2013   10               PED                                               2 h at RT         3000 g/15 min           None                                                       4°C                  Improvement in corneal healing.                                                                                                                                       \[[@B116]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  100% AS                                                 Descriptive prospective observational study                     2011   15               Various ocular surface disorders                  None              10000 rpm/10 min        None                                                       −20°C three months   Redness, burning, sharp pain, and tired eyes improved in 100% of the patients, whereas dryness and sandy/gritty sensation improved in 92% of the patients.            \[[@B70]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS,\                                                Prospective interventional study                                2010   165              PED after PK                                      30 min            1500 rpm/5 min          Sterile saline solution                                    −4°C                 AS improves healing in patients with potentially delayed epithelial heal.                                                                                             \[[@B94]\]
  20% no AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS                                                  Prospective, double-blind randomized crossover study            2014   40               Severe DES                                        2 h at RT         2600 g/10 min           Sterile saline solution                                    −20°C                AS eye drops are more effective than conventional eye drops for improving tear film stability and subjective comfort in patients with severe DES.                     \[[@B93]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  100% AS\                                                Randomized study                                                2013   85               DES/SS, DES/no SS, PED                            5 min at RT       3000 g/5 min            None versus 50% saline or artificial tears or antibiotic   Not provided         AS was the most effective in decreasing symptoms, corneal epitheliopathy, and promoting fast closure of wound.                                                        \[[@B89]\]
  versus normal saline/\                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  artificial tears/\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  antibiotics\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  50% AS                                                  Prospective cross-sectional study                               2014   34               SS                                                2 h at RT         3000 g/15 min           Sodium hyaluronate                                         −70°C until use      AS might not be effective for the treatment of secondary SS because of elevated serum proinflammatory cytokine levels.                                                \[[@B102]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS                                                  Three-month prospective study                                   2014   17               Severe DES                                        Not provided      3000 g/15 min           Isotonic buffered saline solution                          −20°C four months\   The positive effect of AS decreased with time but still persisted up to three months after the end of therapy.                                                        \[[@B103]\]
                                                                                                                                                                                                                                                                                                         4--8°C one week                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS                                                  Double-blind prospective randomized controlled clinical study   2011   32               Acute chemical burns                              Not provided      180 g/10 min            Sterile balanced solution                                  −20°C until use      Umbilical cord serum was more effective than AS and artificial tears in ocular surface restitution.                                                                   \[[@B113]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS versus PRP                                       Retrospective review                                            2012   28               DES                                               Not provided      3000 g/15 min\          Sterile saline solution                                    −20°C until use      The concentrations of GFs in the PRP and AS were not statistically different. PRP could be an effective, novel treatment option for chronic ocular surface disease.   \[[@B71]\]
                                                                                                                                                                                                                      200 g/11 min                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  20% AS versus conventional artificial tears treatment   Double masked randomized\                                       2012   12               Severe DES                                        2 h at RT         3500 rpm/5 min at 4°C   Sterile saline solution                                    −20°C                AS achieves better symptom improvement compared to artificial tears in a short-term treatment.                                                                        \[[@B80]\]
                                                          crossover clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AS: autologous serum; RT: room temperature; CBS: cord blood serum; AMT: amniotic membrane transplantation; PED: persistent epithelial defects; PK: penetrating keratoplasty; DES: dry eye syndrome, SS: Sjogren\'s syndrome; PRP: platelet rich plasma; GFs: growth factors.

###### 

Ongoing controlled clinical studies on serum eye drops from [ClinicalTrials.gov](https://clinicaltrials.gov/).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial registration number                                        Study type                 Patient number   Blood derivatives                                                                                                      Conditions                                                End-point                                                                                                                                                                                                                                                                         Phase
  ---------------------------------------------------------------- -------------------------- ---------------- ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  [NCT01089985](https://clinicaltrials.gov/ct2/show/NCT01089985)   Interventional             10               AS                                                                                                                     Xerophthalmia                                             Efficacy and safety of AS.                                                                                                                                                                                                                                                        Phase 1

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT01972438](https://clinicaltrials.gov/ct2/show/NCT01972438)   Randomized\                44               Autologous serum versus saline solution                                                                                HSCT patients with severe ocular GVHD                     Treatment of severe chronic ocular GVHD in HSCT patients unresponsive to standard medical treatment.                                                                                                                                                                              Phase 1\
                                                                   Intervention\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Phase 2
                                                                   Double-blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT01075347](https://clinicaltrials.gov/ct2/show/NCT01075347)   Randomized\                165              Human autoserum versus traditional medications (0.1% betamethasone, 0.3% gentamicin, and 0.4% tropicamide eye drops)   Corneal epithelial defect,\                               Corneal epithelial healing time by slit-lamp examination with fluorescein staining.                                                                                                                                                                                               Phase 1
                                                                   Intervention Assignment\                                                                                                                                           diabetic retinopathy,\                                                                                                                                                                                                                                                                                                                      
                                                                   Single-blind                                                                                                                                                       penetrating keratoplasty                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT00681642](https://clinicaltrials.gov/ct2/show/NCT00681642)   Observational              7                Human autoserum versus cord blood serum                                                                                Corneal epithelial defect, dry eye syndrome               Wound healing, cell proliferation and migration by means of wound healing assay evaluation, MTS assay, and Boyden chamber migration assay.                                                                                                                                        Completed

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT00442273](https://clinicaltrials.gov/ct2/show/NCT00442273)   Interventional\            48               20% autologous serum and umbilical cord serum eye drops                                                                Severe dry eye syndrome                                   Therapeutic effect between autologous serum and umbilical cord serum eye drops in the treatment of severe dry eye syndrome.                                                                                                                                                       Not provided
                                                                   Nonrandomized\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                   Double-blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT00598299](https://clinicaltrials.gov/ct2/show/NCT00598299)   Observational\             100              Human autoserum versus cord blood serum                                                                                Corneal epithelial defect, dry eye syndrome               Corneal wound healing assay evaluation, MTS assay, and Boyden chamber migration assay                                                                                                                                                                                             Completed
                                                                   Prospective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT01168375](https://clinicaltrials.gov/ct2/show/NCT01168375)   Intervention               80               Umbilical cord serum                                                                                                   Corneal epithelial defect following diabetic vitrectomy   Measurement of corneal epithelial defect in days 3, 5, 7, and 12 by slit lamp.                                                                                                                                                                                                    Phase 1

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT01016158](https://clinicaltrials.gov/ct2/show/NCT01016158)   Interventional\            NP               20% umbilical cord serum eye drops                                                                                     Recurrent corneal erosion                                 Efficacy 20% umbilical cord serum eye drops.                                                                                                                                                                                                                                      Completed
                                                                   Randomized\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                   Single-blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT01234623](https://clinicaltrials.gov/ct2/show/NCT01234623)   Randomized                 30               Cord blood serum                                                                                                       GVHD, Sjogren\'s Disease                                  Healing of corneal epithelial defects, ameliorating the painful subjective symptoms.                                                                                                                                                                                              Phase 1

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT02291731](https://clinicaltrials.gov/ct2/show/NCT02291731)   Interventional\            Not provided     20% autologous serum eye drops and silicone-hydrogel contact lens (CLs)                                                Corneal diseases                                          Clinical effect of combination of topical 20% autologous serum eye drops and CLs in the treatment of recalcitrant PEDs and the recurrence rate of epithelial breakdown with or without continued use of autologous serum eye drops for 2 weeks after total reepithelialization.   Currently recruiting
                                                                   Single-blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT01122303](https://clinicaltrials.gov/ct2/show/NCT01122303)   Observational              20               20% autologous serum eye drops                                                                                         SJS, nonautoimmune dry eye                                Comparisons of the concentrations of EGF, TGF-*β*1, TGF-*β*2, and fibronectin in 20% AS between SJS patients with dry eye and nonautoimmune dry eye patients.                                                                                                                     Unknown

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT00238862](https://clinicaltrials.gov/ct2/show/NCT00238862)   Randomized\                180              Autologous serum 20% versus amniotic membrane transplantation                                                          PED                                                       Corneal reepithelialization, persistent corneal reepithelialization.                                                                                                                                                                                                              Completed
                                                                   single group Open label                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT02153515](https://clinicaltrials.gov/ct2/show/NCT02153515)   Single group\              60               Autologous serum finger prick of blood                                                                                 Dry eyes, PED, ulcers                                     Ulcers time healing (within 4 weeks)\                                                                                                                                                                                                                                             Phase 3
                                                                   Open label                                                                                                                                                                                                                   Improving of corneal and conjunctival staining, Schirmer\'s test, tear break-up time, or symptoms ocular comfort index questionnaire (dry eyes).                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  [NCT00779987](https://clinicaltrials.gov/ct2/show/NCT00779987)   Interventional\            12               20% autologous serum solution                                                                                          Dry eye                                                   Score reduction in the OSDI between patients treated with autologous serum and conventional artificial tears.                                                                                                                                                                     Phase 2
                                                                   study\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                   Double-blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HCST: hematopoietic stem cell transplant; GVHD: chronic graft versus host disease; CLs: silicone-hydrogel contact lens; CLs: silicone-hydrogel contact lens; PED: persistent epithelial defects; SJS: Steven Johnson Syndrome; OSDI: Ocular Surface Disease Index; EGF: epidermal growth factor; TGF-*β*1: transforming growth factor *β*1; TGF-*β*2: transforming growth factor *β*2; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium.
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